Assessment of the French National Experimentation for Incentivising Hospital Prescriptions of Etanercept Biosimilars Delivered in Retail Pharmacies
Author(s)
Tano M1, Degrassat Theas A2, Ribault M3, Paubel P4
1General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP); Health Law Institute, INSERM UMR S 1145, Paris Descartes University; Faculty of pharmacy, Paris Descartes University, Paris, France, 2General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP); Health Law Institute, INSERM UMR S 1145, Paris Descartes ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, 3General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 4General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Law and Health Economics Department, Faculty of Pharmacy & Health Law Institute (INSERM UMR S1145) University of Paris, Paris, France
Presentation Documents
OBJECTIVES: Regarding the low penetration of biosimilars drugs in the French market, the government introduce two incentives to increase biosimilar use. First, the “general case” redirects 20% of the price difference between reference product and its biosimilar to hospitals for every biosimilar delivered in community pharmacy from these hospital’s prescriptions. Second, the “experimental case” increases the premium to 30% by specifically targeting prescribing hospital clinical units for every biosimilar delivered in community pharmacy from these clinical unit’s prescriptions. After a call for proposal, the experimentation started in October 2018. Our study aimed to compare the efficacy of both incentives after 25 months for etanercept biosimilar.
METHODS: We used IQVIA Xponent data to evaluate public hospitals’ prescriptions. The number of etanercept boxes delivered in retail pharmacies was given on a monthly basis, and was linked to the corresponding hospital’s prescription. The comparison between hospitals in the experimentation and the others was assessed by a difference-in-difference method.
RESULT: Among the 39 hospitals studied in the “experimental case”, 92% were public health facilities, of which 21-university hospitals. They were compared to the 255 hospitals belonging to the “general case” group of which 86% were public. In September 2018 before the experiment, the average rate of etanercept biosimilar was 22.4% and 15.4% respectively for experimental and general cases. In October 2020, it was respectively of 52.1% and 36.3% in average. The double difference estimator was 10.85-percentage points. It was significant (p=2.2*10-16) in favor of the experimentation. CONCLUSION: This original incentive directly focused on clinical units appears to be more effective on biosimilar use. Initially planned in October-2021, the end of the experimentation was postponed to May-2022 and suggests the future generalization of this incentive to all hospitals.Conference/Value in Health Info
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
HPR28
Topic
Health Policy & Regulatory
Topic Subcategory
Insurance Systems & National Health Care, Public Spending & National Health Expenditures
Disease
No Additional Disease & Conditions/Specialized Treatment Areas